MD; for the Epidemiological Clinicopathological Studies in Europe (EClipSE) Collaborative Members IMPORTANCE Delirium is associated with accelerated cognitive decline. The pathologic substrates of this association are not yet known, that is, whether they are the same as those associated with dementia, are independent, or are interrelated.
U nderstanding the pathologic basis of cognitive impairment in whole populations is a prerequisite to mitigating the increasing public health burden of dementia. 1 Many strands of investigation presuppose that Alzheimer, vascular, and Lewy body pathologic features are the predominant causes of dementia. This paradigm has directed the search for biomarkers, treatments, and potential prevention strategies. However, evidence indicates that these classic pathologic processes do not fully account for the clinical syndrome, 2 especially in unselected populations of the oldest-old. 3, 4 For example, older people may have a large burden of the pathologic processes of classic dementia but no associated clinical dementia and vice versa. Delirium is a syndrome of acute brain dysfunction characterized by inattention and other mental status impairments. It is a major public health problem that affects at least 20% of older inpatients and has well-documented adverse associations. 5 An emerging literature reveals that delirium is a strong predictor of new-onset dementia and acceleration of existing cognitive decline. [6] [7] [8] [9] [10] These results are consistent across several different settings: after hospitalization, 11 in those with dementia, 6, 12 in postoperative patients, 13 and in a community population. 8 In multiple
animal models of neurodegeneration, triggers of acute cognitive dysfunction, such as systemic inflammation, also exacerbate the pathologic processes 14, 15 and accelerate functional decline during longer periods. 16, 17 This finding implies that delirium and/or its causes can contribute to the overall burden of dementia. Moreover, research indicates that 3 of 10 cases are preventable, 18 which in turn suggests that delirium interventions might reduce at least some cognitive decline and dementia. Although delirium is now established as a strong predictor of cognitive decline in older adults, 6, 8, 12 whether it accounts for additional, interrelated, or unexplained pathologic injury that contributes to dementia has not previously been examined. It is possible that when dementia follows delirium it has a different pathologic profile compared with dementia that develops without delirium. Therefore, understanding how delirium affects the evolution of dementia in the context of a particular burden of pathologic findings may offer new insights into independent mechanisms that explain cognitive decline after delirium. In this study, the challenge was to examine a key hypothesis: that faster cognitive decline associated with delirium would act independently of the cognitive decline associated with the pathologic processes of classic dementia. Accordingly, we investigated the extent to which delirium and the pathologic processes of classic dementia contributed to associated cognitive decline in 3 unselected, population-based cohort studies with neuropathologic autopsy data: the Medical Research Council Cognitive Function and Ageing Study (CFAS), the Cambridge City Over-75s Cohort (CC75C), and the Vantaa 85+ study. These studies represent the entirety of such studies conducted in Europe and provide a unique opportunity to increase the understanding of the clinical significance of delirium and its interrelation with the pathologic processes of dementia in the general population.
Methods
The individual studies have previously been described in detail, 19- Ethics Committee of the City of Vantaa). Written informed consent was provided for each study, and all analyses were conducted with deidentified data.
Delirium Assessments
In the CFAS and CC75C, delirium symptoms were a feature of the standardized interview schedules administered by trained interviewers to participants and informants. These schedules assigned diagnostic groups based on validated, structured algorithms for psychiatric disorders, themselves based on DSM-III-R or related classifications. 25 Questions included the following: "Were there brief episodes during the 24 hours when s/he seemed much worse and then times when quite clear?" "Were there marked fluctuations in his/her level of attention or alertness?" "Could a physical illness…be sufficient explanation for the subject's mental or psychiatric symptoms (eg, delirious due to acute infection)?" A full list of relevant questions is given in the eAppendix in the Supplement. At each interview in the Vantaa 85+ study, the examining neurologists assessed participants and informant(s) for a history of any episodes of delirium, with reference to a checklist of DSM-III-R criteria for delirium diagnosis. 26 The reported history was corroborated with medical case records that were available at the time of assessment such that the study ascertainment of delirium was retrospectively derived from multiple sources and the overall diagnosis accepted if the examining neurologists judged there was sufficient evidence from participant and informant recall and/or indication in the medical records.
Neuropathologic Analyses
Parafin-embedded brain tissue samples were used to assess neuropathologic markers with investigators masked to clinical data. Each study reported Braak stage as a semiquantitative measure of τ neurofibrillary tangles and neocortical amyloid plaque burden from the Consortium to Establish a Registry for Alzheimer's Disease protocol. 27 The presence of infarcts (>10 mm), lacunes, and hemorrhage was histologically assessed using hematoxylin-eosin. Lewy bodies in the substantia nigra were assessed with hematoxylin-eosin but also included immunohistochemical staining against α-synuclein (or ubiquitin in some of the earlier CC75C specimens) (eAppendix in the Supplement).
Statistical Analysis
Consistent with previous approaches, delirium exposure was operationalized as never or ever. 8 Change in MMSE score before death was modeled using a time-to-death randomeffects (random slopes) model. 28 We were interested in estimating the final trajectory toward death because this approach makes associations with pathologic data easier to define. The mean time from the start of the trajectory identified by the model to death was 5.2 years; therefore, the start point (intercept) for this trajectory was set (centered) at 6 years. This start point is not so near the point of death that rates of change (slopes) cannot be estimated yet not so far from death that the pathologic findings at autopsy might not plausibly be related to the estimated parameters. Six years before death is also comparable to start points from change-point models of the final trajectory of cognitive decline [29] [30] [31] and in the range observed in other analyses (3-8 years) . 32 Models were adjusted for baseline MMSE score, age at death (centered at a mean age of 90 years), sex (0 for men, 1 for women), years of education (0-3, 4-7, 8-11, or ≥12), and study. Missing data were assumed to be missing at random given that outcome ascertainment was essentially complete in this brain donor cohort. The 4 neuropathologic variables of classic dementia that contribute the greatest population-attributable risk for dementia 4 were examined: Braak stage (neurofibrillary tangles), neocortical amyloid plaques, vascular pathologic findings (large artery infarcts, lacunes, or hemorrhage), and Lewy bodies in the substantia nigra. In keeping with previous methods, neuropathologic variables were dichotomized (0, none to mild; 1, moderate to severe). 3, 8, 24 This approach allows for simpler interpretation and is more likely to be robust. Individuals were assigned a pathologic burden score based on the number of times they scored in the higher category for each of the 4 markers. Therefore, the overall pathologic burden score ranged from 0 to 4 a Number of surveys refers to the maximum number of times a participant could have been seen up to the most recent follow-up point.
b The CFAS sampled from 6 geographic areas: 4 urban (Newcastle, Nottingham, Liverpool, and Oxford) and 2 rural (Cambridgeshire, Gwynedd).
older, more likely to be women, and more likely to have more years of education. Neocortical amyloid plaques, vascular pathologic findings, or Lewy bodies were not significantly different in individuals with and without a history of delirium.
Results from the random-effects models that described delirium and cognitive decline are presented in Table 3 . The median number of longitudinal observations for participants in the model was 2 (interquartile range, 1-4). In the fully adjusted model (including delirium and pathologic burden), the start point was estimated at 24.7 MMSE points. The start point should be interpreted as the estimated MMSE score 6 years before death in persons in whom all covariates are in the reference category (eg, youngest age, no delirium). For the typical 90-year-old, the mean base rate of decline was 0.35 points per year (base rate indicates all covariates in the reference category, eg, no delirium, lowest pathologic score). There was no significant influence of study source (Vantaa 85+, CC75C, or CFAS) on the model estimates (eAppendix in the Supplement).
Effect of Delirium on Start Point and Rate of Change
Delirium was associated with a mean 2.8-point lower MMSE score (P < .001) 6 years before death. For these persons, the rate of change was an additional 0.37 points per year (P < .001). These coefficients are additive. Therefore, for the typical individual aged 90 years at death with delirium, the estimated MMSE score is 24.7 points (baseline) with −2.8 points equaling 21.9 MMSE points, declining at 0.35 points (base rate) with −0.37 (attributable to delirium) equaling 0.72 points per year.
Effect of Pathologic Burden on Start Point and Rate of Change
An increasing pathologic burden score was associated with a lower MMSE score (−0.7 for 1 instance of high dementia pathologic marker, −2.2 point for 2 markers, and −4.4 for 3 or more markers; P < .001). Pathologic burden conferred an additional 0.39-point decline in MMSE score over and above the effects of age and delirium (P < .001).
Interaction Between Delirium and Pathologic Burden
A significant interaction between delirium and pathologic burden estimated an additional decline of 0.16 MMSE points per year (P = .01). Therefore, individuals with delirium and high dementia pathologic burden had estimated rates of decline of −0.35 points (base rate), −0.37 points (attributable to de- lirium), −0.39 points (attributable to pathologic burden), and −0.16 points (attributable to interaction), which equals 1.27 points per year. In comparison, the independent effect of age alone on the rate of MMSE score change was 0.01 points per year (ie, MMSE score difference of 0.05 between the ages of 85 and 90 years). The Figure shows how the rate of cognitive decline varies by delirium and pathologic status. The slowest decline was seen in persons with no history of delirium and least dementia pathologic burden. The fastest decline was seen in persons with a history of delirium and most dementia pathologic burden. Intermediate rates of decline were observed in individuals with delirium but least dementia pathologic burden and in those with no delirium history but most dementia pathologic burden.
Discussion
This is the first report, to our knowledge, that people with delirium and higher levels of pathologic processes of classic dementia have the greatest cognitive decline. Delirium in the presence of dementia-related neuropathologic processes was associated with cognitive decline beyond that expected for delirium or the neuropathologic process itself. This finding means that delirium may be independently associated with pathologic processes that drive cognitive decline, which are different from the pathologic processes of classic dementia. These findings suggest new possibilities regarding the pathologic correlates of cognitive impairment, positioning delirium, and/or its precipitants as a critically interrelated mechanism.
These results are in keeping with other studies identified in a systematic review 33 reporting that delirium is associated with faster trajectories of cognitive decline. 6, 8, 13 A previous report 8 from the Vantaa 85+ study raised the possibility that the pathologic processes of classic dementia might not mediate the observed association between delirium and dementia, although the analysis was underpowered. In this study, the larger sample size and the more precise determination of cognitive change in the 6 years before death allow us to be more conclusive about the interrelated effect of delirium on clini- copathologic correlations in dementia. Experimental data from mouse models suggest that delirium may arise through the interaction between systemic or central nervous system inflammation and existing neurodegenerative pathologic processes, 34 and acute exacerbation of inflammation clearly leads to neuronal death, 14 synaptic changes, 35 and accelerated decline.
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These changes occur independently of increased extracellular amyloid. However, we now need to know whether individuals with delirium superimposed on dementia have different patterns of inflammation, synaptic loss, axonal pathologic findings, and/or differential loss of key neuronal populations of the hippocampus and cortex and of cholinergic and noradrenergic projection areas.
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Strengths and Limitations
This analysis has a number of strengths. It focuses on a major question arising from the prevalence of cognitive impairment and aging. In terms of study design, the 3 cohorts have high generalizability for the oldest-old populations, who are underrepresented in dementia research despite having the highest prevalence of dementia. 38 This is also the first article, to our knowledge, to examine delirium and the pathologic correlates of cognitive decline at the end of life in the general population; the other analysis comes from a leading study in this area, the Religious Orders cohort study, 30 which is, however, focused on specific populations. Modeling change in cognitive outcomes as continua rather than simply the presence or absence of dementia allows for an exploration of the effect of delirium across the whole spectrum of cognitive function (ie, from no baseline impairment through mild cognitive impairment to more severe dementia severity). The power to assess such effects as interactions between delirium and neuropathologic processes is unique.
A number of limitations should be taken into account. Delirium was retrospectively ascertained and by slightly different methods. In the Vantaa 85+ study, assessments for history of delirium occurred at each visit, using information from participants, informants, and medical records. Ascertainment of data in the CFAS and CC75C relied on diagnostic interviews at each study visit, but these data are likely to underestimate delirium in the intervening period. The diagnostic classification criteria also varied, although the different diagnostic schedules for delirium have good agreement with
DSM-III-R.
39 Despite these differences, the results appear to be consistent across the cohorts. The implication, either way, is that core symptoms in delirium-acute fluctuating change in attention in association with acute illness-represent an adverse state for subsequent cognitive trajectories regardless of the exact methods for operationalizing the syndrome. As with other prospective cohort data, the possibility remains that residual confounding contributes to these observed associations. Another consideration is that only a limited range of pathologic markers and comorbidities could be examined in this harmonized data set. Finally, although recent research based on neuroimaging and neuropathologic examination suggests that insults in earlier life can also be malignant, 40-42 this hypothesis could not be examined within this study.
Conclusions
Our results indicate that delirium interacts with underlying pathologic processes of classic dementia and so represents a potential independent but interrelated pathologic pathway to chronic cognitive impairment and dementia. If delirium prevention could lead to consequent prevention of dementia, 43,44 it will be essential to understand whether certain dimensions of the delirium syndrome might have a greater effect on cognitive trajectories than others. For example, duration, severity, and/or cause (eg, medications vs acute illness, surgery vs sepsis) may be differently important. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
Neuropathology methods
Vantaa 85+
Paraffin embedded tissue samples were assessed for neuropathology. All specimens were performed by one pathologist using exactly the same dissection and examination protocol, blinded to all clinical data. The protocols for assessing Alzheimer type, 1,2 vascular, 3, 4 and Lewy body 5 pathologies have been described previously. After fixation (phosphate buffered 4% formaldehyde for at least two weeks), samples were obtained from the middle frontal, superior temporal and middle temporal gyri, and inferior parietal lobule, according to the standard Consortium to Establish a Registry for Alzheimer's Disease (CERAD) protocol. 6 Alzheimer pathology 10µm sections were stained with a modified Bielschowsky method for neuritic pathology. 6 For scoring, the maximum density of the neuritic plaques was evaluated in the cortical sections. Tissue blocks were embedded in polyethylene glycol 1,000 and then cut (80µm) for free floating staining with the Gallyas silver method for neurofibrillary pathology. 7 Apolipoprotein E (ApoE) genotyping was performed using a combination of polymerase chain reaction and solid phase minisequencing technique. 8 Braak stage is a semi quantitative measure of neurofibrillary tangle load, 9 and was performed without knowledge of clinical diagnosis, neuritic plaque score or ApoE genotype.
Vascular pathology
Cavitary lesions or solid cerebral infarcts visible to the naked eye were identified by examination of the intact brain and from 1 cm thick coronal slices of the cerebral hemispheres, from 5 mm thick transverse slices of the brain stem and sagittal slices of the cerebellum. These lesions were histologically ascertained to be infarcts ( 10mm diameter), lacunes (<10mm) or hemorrhages.
Lewy body pathology
For the assessment of Lewy body pathology, brain samples were obtained following recommendations of the First DLB Consortium International Workshop 10 and assessed for changes in synuclein pathology. 11 Sections of the substantia nigra were stained with the hematoxylin and eosin (H&E) method and with antibodies against synuclein. If any Lewy bodies were detected in the screened areas, the immunohistochemistry for synuclein was performed on cortical samples.
The type of synuclein pathology (none, brainstem predominant, limbic, diffuse neocortical) was determined for every participant. 5 A semiquantitative grading of the cell loss/atrophy in the ventrolateral tier of SN pars compacta was determined from none (0) to severe (3), as reported earlier.
5
City of Cambridge over 75s Cohort
After death, the brains were removed as soon as feasible in the local mortuary. The brains were cut in the sagittal plane. One hemisphere was dissected coronally into approximately one cm slices, macroscopically examined, and snap frozen at 80 C. All assessments were performed blind to clinical status by neuropathologists at Addenbrooke's Hospital, Cambridge, UK.
Alzheimer pathology
The CERAD protocol was followed. Typical Alzheimer's lesions were considered by taking the CERAD ratings for neuritic plaques, diffuse plaques, and neurofibrillary tangles in the following areas:
entorhinal, hippocampal, frontal, temporal, parietal, and occipital. Ratings for tau reactive tangles were estimated according to Braak stage and ratings for neuritic amyloid reactive plaques were estimated according to the age dependent CERAD protocol for all areas.
Tau and amyloid protein were assessed on immunohistochemical preparations using antibodies obtained from the Cambridge Brain Bank Laboratory. Anti tau antibody (mAb 11.57) was used to immunostain neurofibrillary tangles, neuritic plaques, and dystrophic neurites. Plaques were assessed using anti amyloid antibody (DAKO (M872) Clone 6F/3D). Diffuse amyloid reactive plaques were distinguished from neuritic plaques by the presence or absence of dystrophic neurites.
All sections were counterstained with Ehrlich's haematoxylin with 3,3' diaminobenzidine as the chromagen.
Vascular pathology
Microinfarcts, irrespective of age of infarct, were assessed by their presence or absence in the following areas: entorhinal, hippocampal, frontal, temporal, parietal, occipital, deep grey, and other neocortical and subcortical areas. White matter pallor was assessed as present or absent in the occipital, parietal, frontal, temporal cortices, and as pallor in the deep white matter or internal capsule in slides containing the basal ganglia.
Macroscopic vascular burden was assessed by the number, size, and location of visible macrovascular lesions in any area. The age of the infarct or whether they were present in grey or white matter was not noted. The arterial distribution for the largest infarct involved was recorded.
Number of lacunes was recorded in categories of 0, 1-4, 5-9, or 10 or more in each of the following locations: basal ganglia, thalamus, cerebral white matter, brainstem, and other. For diagnostic purposes, blocks for paraffin embedding were taken from: the hippocampus (at the level of the lateral geniculate body), entorhinal cortex (at the level of the mammillary body), frontal, temporal, parietal, and occipital lobes, the basal ganglia, thalamus, pons, medulla, cerebellum, and from two levels of the midbrain. The tissue blocks included subcortical white matter, deep cerebral white matter, and the internal capsule.
Ten micrometer thick sections were stained with hematoxylin and eosin to qualitatively assess white matter pallor, perivascular gliosis, presence of microinfarcts, and microvascular changes in each area sampled. Separate scores were recorded in white and grey matter for V R space expansion, perivascular gliosis, and microinfarcts. Small vessel disease was defined as presence of white matter pallor, perivascular gliosis or 'other' microscopic vascular disease.
Lewy body pathology
Lewy bodies were assessed by their presence or absence in entorhinal, hippocampal, frontal, or temporal areas and, in addition, in the substantia nigra, nucleus basalis, dorsal raphe nucleus, locus coeruleus, and dorsal vagal nucleus. Sections were either immunolabelled with anti ubiquitin antibody (pAb BR 251 DAKO Z0458, early cases) or anti synuclein antibody (Biomol International SA3400, later cases), or stained with haematoxylin and eosin to visualize Lewy bodies..
MRC Cognitive Function and Ageing Study
At necropsy, frozen samples of brain tissue were removed for storage. The remainder of the brain was fixed for standardized assessment on paraffin embedded tissues, following the CERAD protocol with minor modifications (see the MRC CFAS website: www.cfas.ac.uk). Neuropathological examination was carried out without knowledge of clinical or interview data, with semiquantitative rating of specific lesions and a prediction of clinicopathological preliminary diagnosis, according to likely importance. To ensure consistency between the centers, inter rater reliability was addressed at the start of the study, including circulation of macroscopic brain photographs and microscopic slides.
Alzheimer pathology
Amyloid protein pathology and neurofibrillary tangles (NFTs) were assessed in the hippocampus (CA1), entorhinal cortex and in the frontal (Brodman Area 8/9), temporal (BA21), occipital (BA17/18)
